Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease

The COMPASS trial demonstrated that the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events (MACE) in patients with chronic coronary artery disease or peripheral artery disease by 24% during a mean follow-up of 23 months. We explored whether this effect varies by sex.The effects were examined in women and men using log-rank tests and...